Literature DB >> 9409328

Hemostatic factors as predictors of ischemic heart disease and stroke in the Edinburgh Artery Study.

F B Smith1, A J Lee, F G Fowkes, J F Price, A Rumley, G D Lowe.   

Abstract

Plasma fibrinogen is a consistent predictor of ischemic heart disease (IHD) in prospective studies, but there are fewer data relating other hemostatic variables to IHD and also to stroke. We therefore studied the relationships of plasma fibrinogen, von Willebrand factor antigen, tissue plasminogen activator (TPA) antigen, factor VII, and fibrin D-dimer to incidence of IHD and stroke and determined whether any associations could be explained by conventional risk factors and baseline heart disease. In the Edinburgh Artery study, 1592 men and women aged 55 to 74 years, randomly sampled from the general population, were followed prospectively over 5 years to detect fatal and nonfatal IHD and stroke events. During the 5 years, 268 new vascular events were identified. Baseline plasma fibrinogen was independently related to risk of stroke in multivariate analysis that adjusted for cigarette smoking, LDL-cholesterol, systolic blood pressure, and preexisting IHD (relative risk [RR] 1.52, 95% confidence interval [CI] 1.17, 1.98). TPA antigen, and fibrin D-dimer were also independently associated with risk of stroke (RR 1.69,95% CI 1.22,2.35 and RR 1.96, 95% CI 1.12,3.41, respectively). Significant relationships were found between TPA antigen and myocardial infarction (P < or = .05). In older men and women, increased coagulation activity and disturbed fibrinolysis are predictors of future vascular events (both IHD and stroke).

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9409328     DOI: 10.1161/01.atv.17.11.3321

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  32 in total

Review 1.  Role of fibrin D-dimer testing in emergency medicine.

Authors:  A Wakai; A Gleeson; D Winter
Journal:  Emerg Med J       Date:  2003-07       Impact factor: 2.740

2.  The effects of nebivolol on fibrinolytic parameters in mild and moderate hypertensive patients.

Authors:  Bahman Tarighi; Turhan Kurum; Muzaffer Demir; Sen Nur Azcan
Journal:  Can J Cardiol       Date:  2007-06       Impact factor: 5.223

3.  Novel hemostatic factor levels and risk of ischemic stroke: the Atherosclerosis Risk in Communities (ARIC) Study.

Authors:  M Fareed K Suri; Kazumasa Yamagishi; Nena Aleksic; Peter J Hannan; Aaron R Folsom
Journal:  Cerebrovasc Dis       Date:  2010-03-19       Impact factor: 2.762

4.  Plasma haemostatic markers, endothelial function and ambulatory blood pressure changes with home versus hospital cardiac rehabilitation: the Birmingham Rehabilitation Uptake Maximisation Study.

Authors:  K W Lee; A D Blann; K Jolly; G Y H Lip
Journal:  Heart       Date:  2006-06-28       Impact factor: 5.994

Review 5.  Unusual effects of GH deficiency in adults: a review about the effects of GH on skin, sleep, and coagulation.

Authors:  F Tanriverdi; Z Karaca; K Unluhizarci; F Kelestimur
Journal:  Endocrine       Date:  2014-05-11       Impact factor: 3.633

6.  Age and aerobic training status effects on plasma and skeletal muscle tPA and PAI-1.

Authors:  Ryan M Francis; Christine L Romeyn; Adam M Coughlin; Paul R Nagelkirk; Christopher J Womack; Jeffrey T Lemmer
Journal:  Eur J Appl Physiol       Date:  2014-03-07       Impact factor: 3.078

7.  Prognostic value of serum von Willebrand factor, but not soluble ICAM and VCAM, for mortality and cardiovascular events is independent of residual renal function in peritoneal dialysis patients.

Authors:  Jie Dong; Yan-Jun Li; Zhi-Kai Yang; Rong Xu
Journal:  Perit Dial Int       Date:  2014-03-01       Impact factor: 1.756

8.  African-American ethnicity is associated with higher plasma levels of D-dimer in adults with hypertension.

Authors:  M Khaleghi; U Saleem; R D McBane; T H Mosley; I J Kullo
Journal:  J Thromb Haemost       Date:  2008-10-30       Impact factor: 5.824

9.  Associations of activated coagulation factor VII and factor VIIa-antithrombin levels with genome-wide polymorphisms and cardiovascular disease risk.

Authors:  N C Olson; L M Raffield; L A Lange; E M Lange; W T Longstreth; G Chauhan; S Debette; S Seshadri; A P Reiner; R P Tracy
Journal:  J Thromb Haemost       Date:  2017-12-08       Impact factor: 5.824

10.  Atherothrombosis and Thromboembolism: Position Paper from the Second Maastricht Consensus Conference on Thrombosis.

Authors:  H M H Spronk; T Padro; J E Siland; J H Prochaska; J Winters; A C van der Wal; J J Posthuma; G Lowe; E d'Alessandro; P Wenzel; D M Coenen; P H Reitsma; W Ruf; R H van Gorp; R R Koenen; T Vajen; N A Alshaikh; A S Wolberg; F L Macrae; N Asquith; J Heemskerk; A Heinzmann; M Moorlag; N Mackman; P van der Meijden; J C M Meijers; M Heestermans; T Renné; S Dólleman; W Chayouâ; R A S Ariëns; C C Baaten; M Nagy; A Kuliopulos; J J Posma; P Harrison; M J Vries; H J G M Crijns; E A M P Dudink; H R Buller; Y M C Henskens; A Själander; S Zwaveling; O Erküner; J W Eikelboom; A Gulpen; F E C M Peeters; J Douxfils; R H Olie; T Baglin; A Leader; U Schotten; B Scaf; H M M van Beusekom; L O Mosnier; L van der Vorm; P Declerck; M Visser; D W J Dippel; V J Strijbis; K Pertiwi; A J Ten Cate-Hoek; H Ten Cate
Journal:  Thromb Haemost       Date:  2018-01-29       Impact factor: 5.249

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.